Cargando…

Translating tolerogenic therapies to the clinic – where do we stand?

Manipulation of the immune system to prevent the development of a specific immune response is an ideal strategy to improve outcomes after transplantation. A number of experimental techniques exploiting central and peripheral tolerance mechanisms have demonstrated success, leading to the first early...

Descripción completa

Detalles Bibliográficos
Autores principales: Issa, Fadi, Wood, Kathryn J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Research Foundation 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3422982/
https://www.ncbi.nlm.nih.gov/pubmed/22934094
http://dx.doi.org/10.3389/fimmu.2012.00254
_version_ 1782241068309282816
author Issa, Fadi
Wood, Kathryn J.
author_facet Issa, Fadi
Wood, Kathryn J.
author_sort Issa, Fadi
collection PubMed
description Manipulation of the immune system to prevent the development of a specific immune response is an ideal strategy to improve outcomes after transplantation. A number of experimental techniques exploiting central and peripheral tolerance mechanisms have demonstrated success, leading to the first early phase clinical trials for tolerance induction. The first major strategy centers on the facilitation of donor-cell mixed chimerism in the transplant recipient with the use of bone marrow or hematopoietic stem cell transplantation. The second strategy, utilizing peripheral regulatory mechanisms, focuses on cellular therapy with regulatory T cells. This review examines the key studies and novel research directions in the field of immunological tolerance.
format Online
Article
Text
id pubmed-3422982
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Frontiers Research Foundation
record_format MEDLINE/PubMed
spelling pubmed-34229822012-08-29 Translating tolerogenic therapies to the clinic – where do we stand? Issa, Fadi Wood, Kathryn J. Front Immunol Immunology Manipulation of the immune system to prevent the development of a specific immune response is an ideal strategy to improve outcomes after transplantation. A number of experimental techniques exploiting central and peripheral tolerance mechanisms have demonstrated success, leading to the first early phase clinical trials for tolerance induction. The first major strategy centers on the facilitation of donor-cell mixed chimerism in the transplant recipient with the use of bone marrow or hematopoietic stem cell transplantation. The second strategy, utilizing peripheral regulatory mechanisms, focuses on cellular therapy with regulatory T cells. This review examines the key studies and novel research directions in the field of immunological tolerance. Frontiers Research Foundation 2012-08-20 /pmc/articles/PMC3422982/ /pubmed/22934094 http://dx.doi.org/10.3389/fimmu.2012.00254 Text en Copyright © Issa and Wood. http://www.frontiersin.org/licenseagreement This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) , which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.
spellingShingle Immunology
Issa, Fadi
Wood, Kathryn J.
Translating tolerogenic therapies to the clinic – where do we stand?
title Translating tolerogenic therapies to the clinic – where do we stand?
title_full Translating tolerogenic therapies to the clinic – where do we stand?
title_fullStr Translating tolerogenic therapies to the clinic – where do we stand?
title_full_unstemmed Translating tolerogenic therapies to the clinic – where do we stand?
title_short Translating tolerogenic therapies to the clinic – where do we stand?
title_sort translating tolerogenic therapies to the clinic – where do we stand?
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3422982/
https://www.ncbi.nlm.nih.gov/pubmed/22934094
http://dx.doi.org/10.3389/fimmu.2012.00254
work_keys_str_mv AT issafadi translatingtolerogenictherapiestotheclinicwheredowestand
AT woodkathrynj translatingtolerogenictherapiestotheclinicwheredowestand